What is Omeros?
Founded in 1994 and based in Seattle, Omeros is dedicated to the discovery, development, and commercialization of innovative small-molecule and protein therapeutics. The company's strategic focus encompasses both large-market indications and orphan diseases, aiming to address critical unmet medical needs. Omeros' commitment to scientific advancement is evident in its diverse therapeutic areas, positioning it as a key player in the biopharmaceutical landscape.
How much funding has Omeros raised?
Omeros has raised a total of $1.1B across 22 funding rounds:
Stock Offering
$84M
Multiple Rounds
$215M
Stock Offering
$63.6M
Debt
$210M
Stock Offering
$57.5M
Debt
$92.1M
Other Financing Round
$4M
Stock Issuance/Offering (2015): $84M, investors not publicly disclosed
Debt (2016): $50M backed by Oxford Finance and East West Bank
Stock Issuance/Offering (2016): $40M with participation from Cantor Fitzgerald & Co.
Debt (2016): $125M led by CRG LP
Stock Issuance/Offering (2017): $63.6M, investors not publicly disclosed
Debt (2018): $210M, investors not publicly disclosed
Stock Issuance/Offering (2019): $57.5M, investors not publicly disclosed
Debt (2024): $92.1M with participation from Athyrium Capital Management and Highbridge Capital Management
Other Financing Round (2025): $4M led by National Institute on Drug Abuse
Key Investors in Omeros
The Grosvenor Funds
The Grosvenor Funds is an early and expansion-stage venture capital firm. Founded in 1994, Grosvenor is currently investing its fourth fund and has invested in over 70 private companies. Grosvenor, a Small Business Investment Company ("SBIC"), invests primarily in technology companies with proprietary intellectual property serving large, existing markets.
Southern Cross Venture Partners
Southern Cross Venture Partners backs promising entrepreneurs to build successful companies with global potential. The funds are currently focused on technology, energy and resources at the seed, early and growth stages. We are uniquely placed to help entrepreneurs through our presence in Australia, Silicon Valley and Asia through our partnership with SBCVC. We assist our entrepreneurs by catalysing the right connections, bringing the lessons of experience, acting as a trusted partner and sharing in the vision of our entrepreneurs to build great companies.
ARCH Ventures
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Omeros?
The recent major strategic investment suggests Omeros is poised for accelerated expansion and further clinical development. This capital infusion is likely to bolster research and development efforts, potentially enabling the company to advance its lead candidates through late-stage trials and prepare for commercialization. The company's trajectory indicates a strong focus on leveraging its scientific expertise to bring novel treatments to patients, with future growth expected to be driven by successful product launches and strategic partnerships.
See full Omeros company page
